Literature DB >> 24661907

Sox9 and Hif-2α regulate TUBB3 gene expression and affect ovarian cancer aggressiveness.

Giuseppina Raspaglio1, Marco Petrillo2, Enrica Martinelli2, Domenica Donatella Li Puma2, Marisa Mariani3, Marta De Donato2, Flavia Filippetti2, Simona Mozzetti2, Silvia Prislei2, Gian Franco Zannoni4, Giovanni Scambia5, Cristiano Ferlini6.   

Abstract

UNLABELLED: SOX9 [(sex determining region Y)-box9] gene has been implicated in the development and progression of different neoplasms. This study investigated the role of Sox9 in the expression of TUBB3 gene, a marker of aggressiveness in ovarian cancer (OC), encoding βIII-tubulin protein. Gene expression was assessed by quantitative polymerase chain reaction (qPCR) in OC models. Using chromatin immunoprecipitation (ChIP) we found that Sox9 engages TUBB3 promoter at minus 980 base pairs from the transcriptional start site with transcriptional enhancing effects. Furthermore we found that Sox9 is a downstream target of Hif-2α, a transcription factor encoded by endothelial PAS domain protein-1 (EPAS1). Hypoxic microenvironment is a common feature of solid tumors associated with cancer aggressiveness. In the present work we found that knockdown of either SOX9 or EPAS1 abolished TUBB3 gene induction in hypoxia. This phenomenon was associated with a decrease in the number of cell colonies capable of growing in an anchorage-independent way. Using a nanofluidic genetic analyzer, the expression of SOX9, TUBB3 and EPAS1 was evaluated in 182 OC specimens. Double staining immunohistochemistry was employed to evaluate the expression and prognostic role of both Sox9 and βIII-tubulin. Results obtained in cellular models matched the pattern of clinical specimens. We documented a direct correlation among the expression of EPAS1, SOX9 and TUBB3 at mRNA level. Patients displaying no expression for the three genes had the best outcome. A poor prognosis significant in multivariate analysis was visible in patients featuring high expression of βIII-tubulin and nuclear Sox9.
CONCLUSIONS: Sox9 allows the survival of OC cells upon hypoxic condition, through the activation of βIII-tubulin expression and its aberrant activation in OC is prominent in patients with aggressive OC.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Ovarian cancer; Poor prognosis; SOX9; Tumor hypoxia; βΙΙΙ-tubulin

Mesh:

Substances:

Year:  2014        PMID: 24661907     DOI: 10.1016/j.gene.2014.03.037

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  28 in total

1.  Integration and bioinformatics analysis of DNA-methylated genes associated with drug resistance in ovarian cancer.

Authors:  Bingbing Yan; Fuqiang Yin; Q I Wang; Wei Zhang; L I Li
Journal:  Oncol Lett       Date:  2016-05-18       Impact factor: 2.967

Review 2.  The role of hypoxic signalling in metastasis: towards translating knowledge of basic biology into novel anti-tumour strategies.

Authors:  Joaquín Araos; Jonathan P Sleeman; Boyan K Garvalov
Journal:  Clin Exp Metastasis       Date:  2018-08-31       Impact factor: 5.150

3.  Expression and Therapeutic Potential of SOX9 in Chordoma.

Authors:  Hua Chen; Cassandra C Garbutt; Dimitrios Spentzos; Edwin Choy; Francis J Hornicek; Zhenfeng Duan
Journal:  Clin Cancer Res       Date:  2017-06-12       Impact factor: 12.531

Review 4.  Susceptibility of cytoskeletal-associated proteins for tumor progression.

Authors:  Abiola Abdulrahman Ayanlaja; Xiaoliang Hong; Bo Cheng; Han Zhou; Kouminin Kanwore; Piniel Alphayo-Kambey; Lin Zhang; Chuanxi Tang; Muinat Moronke Adeyanju; Dianshuai Gao
Journal:  Cell Mol Life Sci       Date:  2021-12-29       Impact factor: 9.261

5.  Decreased expression of SOX9 indicates a better prognosis and inhibits the growth of glioma cells by inducing cell cycle arrest.

Authors:  Jing Gao; Jia-Yi Zhang; Yu-Hong Li; Fu Ren
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

6.  MBD3 mediates epigenetic regulation on EPAS1 promoter in cancer.

Authors:  Jie Cui; Biao Duan; Xuyang Zhao; Yan Chen; Shixun Sun; Wenjie Deng; Yujie Zhang; Jun Du; Yongchang Chen; Luo Gu
Journal:  Tumour Biol       Date:  2016-07-27

7.  Nek6 and Hif-1α cooperate with the cytoskeletal gateway of drug resistance to drive outcome in serous ovarian cancer.

Authors:  Marta De Donato; Mara Fanelli; Marisa Mariani; Giuseppina Raspaglio; Deep Pandya; Shiquan He; Paul Fiedler; Marco Petrillo; Giovanni Scambia; Cristiano Ferlini
Journal:  Am J Cancer Res       Date:  2015-05-15       Impact factor: 6.166

8.  Sox9 regulates hyperexpression of Wnt1 and Fzd1 in human osteosarcoma tissues and cells.

Authors:  Huancai Liu; Yanchun Chen; Fenghua Zhou; Linlin Jie; Leidong Pu; Jie Ju; Fengjie Li; Zhigang Dai; Xin Wang; Shuanhu Zhou
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15

9.  Dexmedetomidine upregulates microRNA-185 to suppress ovarian cancer growth via inhibiting the SOX9/Wnt/β-catenin signaling pathway.

Authors:  Hang Tian; Lei Hou; Yumei Xiong; Qiuju Cheng
Journal:  Cell Cycle       Date:  2021-04-04       Impact factor: 4.534

10.  LINC00115 promotes stemness and inhibits apoptosis of ovarian cancer stem cells by upregulating SOX9 and inhibiting the Wnt/β-catenin pathway through competitively binding to microRNA-30a.

Authors:  Rui Hou; Luo Jiang
Journal:  Cancer Cell Int       Date:  2021-07-08       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.